For over a year, the Pathways Home plan has been working to build the system of their 5-year plan. Earlier this week, they announced that 100 families have gone from homeless to housed since the ...
LATS1/2-inactivation and consequent nuclear YAP/TAZ hyperactivation in the mammary epithelium drives the development of a pro ...
French biotech Inventiva’s layoffs and pipeline shift are expected to help keep the company operational into the second half of 2026.
A phase 3 trial of lanifibranor, a pan-PPAR agonist, in patients with MASH and liver fibrosis is ongoing. But with the 96.6 ...